SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology. 1991;19:403410.
  • 2
    Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up [C.W. Elston & I.O. Ellis. Histopathology 1991;19:403–410]. Histopathology. 2002;41:151153
  • 3
    Galea MH, Blamey RW, Elston CE, et al. The Nottingham Prognostic Index in primary breast cancer. Breast Cancer Res Treat. 1992;22:207219.
  • 4
    Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumors. Nature. 2000;406:747752.
  • 5
    Sorlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A. 2001;98:1086910874.
  • 6
    Weigelt B, Baehner FL, Reis-Filho JS. The contribution of gene expression profiling to breast cancer classification, prognostication and prediction: a retrospective of the last decade. J Pathol. 2009;220:263280.
  • 7
    Foulkes WD, Smith IE, Reis-Filho JR. Triple-negative breast cancer. N Engl J Med. 2010;363:19381948.
  • 8
    Aebi S, Sun Z, Braun D, et al. Differential efficacy of three cycles of CMF followed by tamoxifen in patients with ER-positive and ER-negative tumors: long-term follow up on IBCSG Trial IX. Ann Oncol. 2011;22:19811987.
  • 9
    Wo JY, Taghian AG, Nguyen PL, et al. The association between biological subtype and isolated regional nodal failure after breast-conserving therapy. Int J Radiat Oncol Biol Phys. 2010;77:188196.
  • 10
    Ogino S, Fuchs CS, Giovannucci E. How many molecular subtypes? Implications of the unique tumor principle in personalized medicine. Expert Rev Mol Diagn. 2012;12:621628.
  • 11
    Nielsen TO, Hsu FD, Jensen K, et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res. 2004;10:53675374.
  • 12
    Dolled-Filhart M, Ryden L, Cregger M, et al. Classification of breast cancer using genetic algorithms and tissue microarrays. Clin Cancer Res. 2006;12:64596468.
  • 13
    Blows FM, Driver KE, Schimdt MK, et al. Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and term survival: a collaborative analysis of data for 10,159 cases from 12 studies [serial online]. PLoS Med. 2010;7:e1000279.
  • 14
    Westman-Naeser S, Bengtsson E, Eriksson O, et al. Multifocal breast carcinoma. Am J Surg. 1981;142:255257.
  • 15
    Egan RL. Multicentric breast carcinomas: clinical-radiographic-pathologic whole organ studies and 10-year survival. Cancer. 1982;49:11231130.
  • 16
    Holland R, Veiling SH, Mravunac M, et al. Histologic multifocality of Tis, T1-2 breast carcinomas. Implications for clinical trials of breast conserving surgery. Cancer. 1985;56:979990.
  • 17
    Tot T. Axillary lymph node status in unifocal, multifocal, and diffuse breast carcinomas: differences are related to macrometastatic disease. Ann Surg Oncol. 2012;19:33953401.
  • 18
    Weissenbacher TM, Zschage M, Janni W, et al. Multicentric and multifocal versus unifocal breast cancer: is the tumor-node-metastasis classification justified? Breast Cancer Res Treat. 2010;122:2734.
  • 19
    Boyages J, Jayasinghe UW, Coombs N. Multifocal breast cancer and survival: each focus does matter particularly for larger tumours. Eur J Cancer. 2010;46:19901996.
  • 20
    Bendifallah S, Werkoff G, Borie-Moutafoff C, et al. Multiple synchronous (multifocal and multicentric) breast cancer: clinical implications. Surg Oncol. 2010;19:e115e123.
  • 21
    Tot T, Gere M, Pekar Gy, et al. Breast cancer multifocality, disease extent, and survival. Hum Pathol. 2011;42:17611769.
  • 22
    Garimella V, Long ED, O'Kane SL, et al. Oestrogen and progesterone status of individual foci in multifocal invasive ductal cancer. Acta Oncol. 2007;46:204207.
  • 23
    Buggi F, Folli S, Curcio A, et al. Multicentric/multifocal breast cancer with a single histotype: is the biological characterization of all individual foci justified? Ann Oncol. 2012;23:20422046.
  • 24
    Choi Y, Kim EJ, Seol H, et al. The hormone receptor, human epidermal growth factor receptor 2, and molecular subtype status of individual tumor foci in multifocal/multicentric invasive ductal carcinoma of breast. Hum Pathol. 2012;43:4855.
  • 25
    Tot T. The clinical relevance of the distribution of the lesions in 500 consecutive breast cancer cases documented in large-format histological sections. Cancer. 2007;7:581587.
  • 26
    Tavassoli FA, Devilee P, eds. World Health Organization Classification of Tumours: Pathology and Genetics. Tumours of the Breast and Female Genital Organs. Lyon, France: IARC Press; 2003.
  • 27
    Tot T. Early and more advanced unifocal and multifocal breast carcinomas and their molecular phenotypes. Clin Breast Cancer. 2011;11:258263.
  • 28
    Goldhirsch A, Wood WC, Coates AS, et al. Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol. 2011;22:17361747.
  • 29
    Sotiriou C, Wiraparti P, Loi S, Harris A et al. Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst. 2006;98:262272
  • 30
    Sotiriou C, Pusztai L. Gene-expression signatures in breast cancer. N Engl J Med. 2009;360:790800.
  • 31
    Lester SC, Bose S, Chen YY, et al; Members of the Cancer Committee, College of American Pathologists. Protocol for the examination of specimens from patients with invasive carcinoma of the breast. Arch Pathol Lab Med. 2009;133:15151538.
  • 32
    Tot T, Tabar L, Dean PB. Practical Breast Pathology. Stuttgart, Germany: Thieme; 2002.
  • 33
    Boros M, Marian C, Moldovan C, Stolnicu S. Morphological heterogeneity of the simultaneous ipsilateral invasive tumor foci in breast carcinoma: a retrospective study of 418 cases of carcinomas. Pathol Res Pract. 2012;208:604609.
  • 34
    Gallager HS, Martin JE. The study of mammary carcinoma by mammography and whole organ sectioning. Early observations. Cancer. 1969;23:855873.
  • 35
    Tot T. Subgross morphology, the sick lobe hypothesis, and the success of breast conservation [serial online]. Int J Breast Cancer. 2011;2011:634021.
  • 36
    Tucker FL. Imaging-assisted large-format breast pathology: program rationale and development in a nonprofit health system in the United States [serial online]. Int J Breast Cancer. 2012;2012:171792.
  • 37
    Tot T, Pekar G. Multifocality in “basal-like” breast carcinomas and its influence on lymph node status. Ann Surg Oncol. 2011;18:16711677.
  • 38
    Tot T. The role of large-format histopathology in assessing subgross morphological prognostic parameters: a single institution report of 1000 consecutive breast cancer cases [serial online]. Int J Breast Cancer. 2012;2012:395415.
  • 39
    Joergensen LE, Gunnarsdottir KA, Lanng C, et al. Multifocality as a prognostic factor in breast cancer patients registered in Danish Breast Cancer Cooperative Group (DBCG) 1996–2001. Breast. 2008;17:587591.
  • 40
    Pekar G, Hofmeyer S, Tabar L, et al. Multifocal breast cancer documented in large-format histology sections: long-term follow-up results by molecular phenotypes. Cancer. 2013;119:11321139.
  • 41
    Desmedt C, Nik-Zainal S, Fumagalli D, et al.Characterization of different foci of multifocal breast cancer using genomic, transcriptomic and epigenomic data [abstract]. Abstracts: Thirty-Fifth Annual CTRC-AACR San Antonio Breast Cancer Symposium; December 4–8, 2012; San Antonio, TX. Cancer Res. 2012;72(24 suppl). Abstract nr S60–2.